×

Drop in medicine exports

New figures show there has been a 30 per cent drop in Australia’s exported manufactured medicines in the past few years, with industry warning solutions to high manufacturing costs need to be addressed to compete, or risk losing out to growing markets in Asia.

Australian Bureau of Statistics trade figures released last month found Australia’s pharmaceutical export industry is now worth about $2.5 billion a year, a significant drop from 2012 when it was worth more than $4 billion.

Pharmaceutical exports have now fallen behind car exports and are on track to drop behind the wine export industry, which is worth just more than $2 billion a year.

The data has underlined recent warnings from Medicines Australia who say that an increasingly unstable business operating environment is discouraging companies, citing high wages, taxes, and a tangle of regulations.

Medicines Australia said that to further support the pharmaceutical industry the Government must identify additional ways to encourage more local innovation and adopt policies that will lead to more research and development, clinical trials, and advanced manufacturing investment.

The strong Australian dollar through much of 2012-2014 is another key factor in manufacturing competitiveness.

The Abbott Government has started putting in steps to overhaul drug cost reimbursement rules in order to ramp down costs, while at the same time setting up funding for biomedical research that could lead to more innovative drugs discovered locally.

A spokesperson for Industry and Science Minister Ian Macfarlane told the Sydney Morning Herald that the Government had identified medical technologies and pharmaceuticals as a key economic area in which Australia has the best potential to compete internationally and in which we can create new economic opportunities.

The spokesperson said the Government has chosen the sector for one of five new industry growth centres and added that the pharmaceuticals sector has been strengthened by a $50 million manufacturing transition program and a recently established health industry forum led by Mr Macfarlane and Health Minister Sussan Ley.

 

Kirsty Waterford

News briefs

“Post-Ebola syndrome” dogs survivors

Many survivors of the recent Ebola epidemic in West Africa are now returning to clinics complaining of mysterious symptoms: chronic headaches, debilitating joint pain, even eye problems that can progress to blindness, Wired reports. Doctors in the region have begun calling the suite of problems “post-Ebola syndrome” (PES) and they’re developing clinics devoted to caring for Ebola survivors. Until the latest epidemic, evidence of PES has been hard to find because survivors were rare. “But this most recent outbreak was unusual in the number of people who survived it — a new population to study. With 15 000 or so confirmed survivors in West Africa, epidemiologists ought to be able to nail down which symptoms are caused by Ebola infection”, rather than other suspects like Lassa fever or malaria.

Jail sentences for Bangladeshi paracetamol syrup poisoners

Six senior employees of the now-closed drug company BCI Bangladesh have been handed 10-year jail sentences for making toxic paracetamol syrup which allegedly killed hundreds of children in the 1990s, AFP reports. The men were charged in 2009 after it was found that the syrup had been adulterated with diethylene glycol, commonly used in the leather industry, and 10 times cheaper than the safe propylene glycol. Only one of the six men will go to jail, however, as the other five are still on the run. “Mohammed Hanif, a top paediatric nephrologist, has told AFP that local hospitals first started seeing children with kidney failure in late 1982. But it took another 10 years to establish the deaths were due to diethylene glycol. By then, Hanif says several thousand children had died.”

Second case of plague reported in California

Californian health officials are investigating another possible case of plague in a tourist who fell ill after visiting Yosemite National Park, the Sierra National Forest and surrounding areas — the second case in less than a month, Associated Press reports. “A child fell ill with the plague after camping with his family at Yosemite’s Crane Flat Campground in mid-July. The park reopened Crane Flat last week after treating it for four days with an insecticide. Park officials closed the Tuolumne Meadows Campground from noon Monday through noon Friday so authorities can treat the area with a flea-killing insecticide after two squirrels died of plague in the area.” A spokesperson for the Californian Department of Public Health said the risk to human health “remains low”.

Zebrafish doing their bit for diabetics

ScienceDaily reports that a group of American scientists are claiming to have identified 24 drug candidates that increase the number of insulin-producing cells in the pancreas, via experiments with 500 000 genetically modified zebrafish embryos. The transparent zebrafish embryos were modified so their insulin-producing pancreatic cells glowed yellow, and non-insulin-producing cells glowed red. Using high-throughput screening — using robotic equipment to dose tens of thousands of samples daily — researchers tested thousands of compounds from a Johns Hopkins library of drugs for ones that increased the amount of yellow glow. Originally reported in eLife, Associate Professor Jeffrey Mumm, professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute, says that while more research was needed, “we think there’s potentially no limit on the diseases this screening technique could be applied to other than the human imagination”.

Pilots’ prostates can rest easier

Pilots concerned their risk of prostate cancer was elevated can breathe easier after the retraction of a recent meta-analysis that found they are at least twice as likely to develop the disease, Retraction Watch reports. The paper, recently published in Aerospace Medicine and Human Performance, was retracted for “including inappropriate data from two studies that should be ineligible”. The paper reviewed eight studies, but included two articles that reported on prostate cancer in all United States Armed Forces servicemen, and not just pilots. First author David Raslau, from the Mayo Clinic, apologised, saying: “I was at the infancy of my training in Aerospace Medicine … When I began working on this research project, the phrase ‘Air Force servicemen’ seemed equivalent to the term pilots to me. Now after having completed training in this field, I can easily see the folly of this assumption”.

[Editorial] A global assessment of dementia, now and in the future

Last week, thousands of fantasy fiction fans queued to buy Terry Pratchett’s final book, The Shepherd’s Crown, which was released nearly 6 months after his death following a long battle with posterior cortical atrophy, a rare form of dementia. The much-loved author was an ardent advocate for Alzheimer’s Research UK, raising awareness of the need for increased funding and more research on the disease. In the same week, less publicised but more important for patients with dementia, their families, and health-care providers, Alzheimer’s Disease International (ADI) released its 2015 World Alzheimer Report, which this year focuses on the global effect of dementia, and provides projected estimates of the prevalence, incidence, and societal and economic consequences of dementia up to 2050.

[Editorial] Paolo Macchiarini is not guilty of scientific misconduct

Last week, allegations of research misconduct against Paolo Macchiarini, a professor at the Karolinska Institute in Stockholm, Sweden, were finally dismissed. The university issued its final ruling, concluding that there was “nothing to support suspicions of scientific misconduct”. Macchiarini’s work on the transplantation of tissue-engineered tracheas was published in The Lancet in 2011. This article, and several further research and review papers, were the targets of criticism by some of Macchiarini’s former colleagues.

[Obituary] Annik Rouillon

Tuberculosis researcher and public health advocate who worked to control the disease in developing countries. She was born in 1929 in Châteauroux, France, and died there on July 13, 2015, age 85 years.

[Correspondence] Reforming public and global health research in Germany

The Lancet Editorial1 commends the report2 from two German scientific academies and the union of the German academies of sciences and humanities about reforming public health in Germany as an “invaluable road map”. The report2 finds weaknesses in Germany’s public and global health efforts, ascribing them to a fragmentation of research activities and people and institutions engaged in public health. It suggests four scenarios for reform that are all aimed towards an increasingly centralised or coordinated structure.

[Editorial] An Ebola vaccine: first results and promising opportunities

Today, The Lancet publishes the first results from a phase 3 cluster randomised trial of a novel Ebola virus vaccine. The study, sponsored and led by WHO, is a remarkable scientific and logistical achievement. In the midst of an extreme public health emergency, researchers, health workers, and community facilitators in Guinea included 7651 people in a trial to test the efficacy of a recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Ebola (Zaire).

[Perspectives] Marcia Stefanick: women’s west coast initiatives lead to wisdom

In a career devoted to rattling the defensive bars of received wisdom, Marcia Stefanick’s restless scrutiny of the status quo has lighted on a new target: human biology. “At this point I feel strongly that some of our basic biology is wrong. It may not be profoundly wrong. It may in some cases just need tweaking. But in other cases I feel it is wrong.” The specific area in which she believes it to be failing is the longstanding neglect of sex differences. “If you look at basic science there’s a predominance of male animals, male rodents.” In the past, much the same was true of many clinical trials and other human research studies.

[Correspondence] Rhesus disease: a major public health problem

We admire The Lancet’s Clinical Campaigns focusing the expertise of researchers and scientists to effect changes in management of diseases.1 The focus has been on major disorders that affect millions of people in high-income, low-income, and middle-income regions of the world. We believe minor issues that are immediately solvable but that need engagement with policy makers and other advocates for change likewise need attention.